These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33598648)

  • 1. Gut dysbiosis as a driver in alcohol-induced liver injury.
    Fairfield B; Schnabl B
    JHEP Rep; 2021 Apr; 3(2):100220. PubMed ID: 33598648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Medical Treatment for Alcohol-Associated Liver Disease.
    Ayares G; Idalsoaga F; Díaz LA; Arnold J; Arab JP
    J Clin Exp Hepatol; 2022; 12(5):1333-1348. PubMed ID: 36157148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiome and Alcohol-associated Liver Disease.
    Philips CA; Schnabl B; Bajaj JS
    J Clin Exp Hepatol; 2022; 12(5):1349-1359. PubMed ID: 36157139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
    Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
    Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
    Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease.
    Robinson KE; Shah VH
    Transl Gastroenterol Hepatol; 2020; 5():49. PubMed ID: 33073044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of farnesoid X receptor and bile acids in alcoholic liver disease.
    Manley S; Ding W
    Acta Pharm Sin B; 2015 Mar; 5(2):158-67. PubMed ID: 26579442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Pharmacotherapies in Alcohol-Associated Hepatitis.
    Wakil A; Niazi M; Meybodi MA; Pyrsopoulos NT
    J Clin Exp Hepatol; 2023; 13(1):116-126. PubMed ID: 36647403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis.
    Spatz M; Ciocan D; Merlen G; Rainteau D; Humbert L; Gomes-Rochette N; Hugot C; Trainel N; Mercier-Nomé F; Domenichini S; Puchois V; Wrzosek L; Ferrere G; Tordjmann T; Perlemuter G; Cassard AM
    JHEP Rep; 2021 Apr; 3(2):100230. PubMed ID: 33665587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Management and Future Treatment of Alcoholic Hepatitis.
    Mitchell MC; Kerr T; Herlong HF
    Gastroenterol Hepatol (N Y); 2020 Apr; 16(4):178-189. PubMed ID: 34035720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum, Screening, and Diagnosis of Alcohol-related Liver Disease.
    Hernandez-Tejero M; Clemente-Sanchez A; Bataller R
    J Clin Exp Hepatol; 2023; 13(1):75-87. PubMed ID: 36647416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids.
    Way GW; Jackson KG; Muscu SR; Zhou H
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.
    Arab JP; Arrese M; Shah VH
    Hepatol Res; 2020 Apr; 50(4):407-418. PubMed ID: 31840358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcohol, the gut microbiome, and liver disease.
    Jew MH; Hsu CL
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1205-1210. PubMed ID: 37096652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.